Back close

In silico analysis of drug resistance in wild type and mutant HIV-1 subtype D protease

Publication Type : Journal Article

Source : BMC Infectious Diseases, 2014

Url :

Campus : Bengaluru

School : School of Artificial Intelligence

Verified : No

Year : 2014

Abstract : Background A general cause for therapeutic failure in people is due to the high resistance of HIV protease to antiretroviral drugs. The aim of the present work is focused on two objectives: to study the mutations responsible for the drug resistance using Stanford database and how the existing ART drugs are resistant to subtype d (wild type, major and minor mutations) using docking studies. Methods The mutation frequency of subtype d in untreated persons was obtained from Stanford DR database, http://hivdb. stanford. edu/. Based on the database the wild type PTD sequence was generated. Crystal structure 3LZS showed more similarity based on BLASTp program. The protein structure 3LZS was used as a template to build wild type, major (L10V, N37D, K69Y), minor (K20I, L33I, P39T, Q61N), major+ minor mutants of PTD using Modeller9v7. The docking studies of protease inhibitors (atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir) with the wild type and mutant models were carried using AutoDock 4.2. 5. Results The docking studies revealed that contribution of high torsional energy in atazanavir affects the binding energy and leads to high level resistance to the wild type and the mutants. Indinavir showed susceptibility for the wild type PTD whereas nelfinavir showed susceptibility to all mutants and the susceptibility was due to less number of torsions and increased van der Waals, hydrogen bonding, desolvation and electrostatic energy contributions. Conclusion The developed wild type and mutant model of PTD provides an insight to understand the effect of mutations and resistance towards the protease inhibitors.

Cite this Research Publication : Vasavi CS and Munusami P. In silico analysis of drug resistance in wild type and mutant HIV-1 subtype D protease. BMC Infectious Diseases, 2014;14:E23 BMC, Impact Factor: 1.58

Admissions Apply Now